Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 4 Evaluation of patients’ SF-36 quality of life scores

From: The effectiveness of kinesiotaping in treating chronic lateral epicondylitis: a randomized, sham-controlled, single-blind study

Variable

KT Group (n = 21)

Sham Group (n = 21)

Between-group analysis (pa)

Physical Functioning

W0

65 (60–83)

75 (50–75)

0.723a

W3

90 (80–100)

80 (50–90)

0.101a

W7

100 (85–100)

85 (50–98)

0.210a

Pc

< 0.001

0.071

 

W0-3 (pb)

< 0.001

0.105

W0-7 (pb)

< 0.001

0.014

W3-7 (pb)

0.125

0.260

Social Functioning

W0

88 (50–100)

100 (63–100)

0.576a

W3

100 (88–100)

100 (63–100)

0.307a

W7

100 (88–100)

100 (63–100)

0.314a

Pc

0.001

0.076

 

W0-3 (pb)

0.005

0.040

W0-7 (pb)

0.005

0.056

W3-7 (pb)

0.564

0.317

Physical Role Limitations

W0

0 (0-100)

0 (0–0)

0.01a

W3

100 (75–100)

0 (0–0)

< 0.001a

W7

100 (88–100)

0 (0–0)

< 0.001a

Pc

0.001

0.565

 

W0-3 (pb)

0.001

0.106

W0-7 (pb)

< 0.001

0.106

W3-7 (pb)

0.890

1.0

Emotional Role Limitations

W0

0 (0-100)

0 (0-100)

0.932a

W3

100 (100–100)

100 (0-100)

0.023a

W7

100 (100–100)

100 (0-100)

0.032a

Pc

< 0.001

0.018

 

W0-3 (pb)

0.099

0.001

W0-7 (pb)

< 0.001

0.905

W3-7 (pb)

< 0.001

< 0.001

Pain

W0

35 (16–56)

23 (5–35)

0.232a

W3

90 (56–95)

45 (28–58)

< 0.001a

W7

90 (58–100)

45 (28–56)

< 0.001a

Pc

< 0.001

0.009

 

W0-3 (pb)

< 0.001

0.007

W0-7 (pb)

< 0.001

0.009

W3-7 (pb)

0.833

0.490

Vitality (Energy)

W0

65 (50–78)

50 (38–78)

0.23a

W3

80 (75–90)

50 (40–70)

0.001a

W7

80 (75–90)

50 (40–68)

< 0.001a

Pc

< 0.001

1.0

 

W0-3 (pb)

0.001

0,779

W0-7 (pb)

< 0.001

0.726

W3-7 (pb)

0.674

0.655

Mental Health

W0

68 (62–82)

64 (46–74)

0.121a

W3

73 (61–75)

45 (41–57)

< 0.001a

W7

88 (78–92)

60 (52–72)

< 0.001a

Pc

< 0.001

< 0.001

 

W0-3 (pb)

0.099

0.001

W0-7 (pb)

< 0.001

0.905

W3-7 (pb)

< 0.001

< 0.001

General Health

W0

60 (46–68)

45 (35–68)

0.270a

W3

70 (60–80)

55 (43–60)

< 0.001a

W7

75 (60–75)

50 (39–60)

< 0.001a

Pc

< 0.001

0.343

 

W0-3 (pb)

0.001

0.394

W0-7 (pb)

0.001

0.858

W3-7 (pb)

0.803

0.257

  1. KT, kinesiotaping; SF-36, Short form-36; a Mann-Whitney U test; Pc Friedman test; b Wilcoxon Signed-Ranks test; W0-3, W0-7, W3-7: Pre-post treatment differences; Median (1st quartile–3rd quartile) for non-normal distribution values were used. Adjusted p-values were considered significant based on Bonferroni correction
  2. W0: Baseline assessment (pre-treatment)
  3. W3: Assessment immediately after treatment completion (week three)
  4. W7: Assessment 4 weeks after treatment completion (week seven)